Cytomed Therapeutics Limited (GDTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 12-2024 | 06-2024 | 12-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,766 | -1,846 | -803 | -3,132 | -1,596 |
| Depreciation Amortization | 141 | 245 | 123 | 289 | 150 |
| Accounts receivable | -143 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 29 | N/A | N/A | N/A | N/A |
| Other Working Capital | -137 | -44 | -126 | 80 | -196 |
| Other Operating Activity | 618 | -339 | -47 | 162 | 137 |
| Operating Cash Flow | $-1,257 | $-1,984 | $-853 | $-2,602 | $-1,504 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 215 | N/A | N/A | N/A | N/A |
| PPE Investments | -273 | -1,025 | -427 | -44 | -13 |
| Other Investing Activity | 41 | 1,850 | -966 | -2,100 | 0 |
| Investing Cash Flow | $-18 | $825 | $-1,393 | $-2,144 | $-13 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -5 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -23 | -48 | -22 | 8,277 | 8,075 |
| Financing Cash Flow | $-27 | $-48 | $-22 | $8,277 | $8,075 |
| Exchange Rate Effect | -146 | 89 | 53 | -10 | -9 |
| Beginning Cash Position | 3,693 | 4,556 | 6,637 | 1,197 | 1,168 |
| End Cash Position | 2,245 | 3,438 | 4,423 | 4,718 | 7,719 |
| Net Cash Flow | $-1,448 | $-1,118 | $-2,215 | $3,520 | $6,550 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,257 | -1,984 | -853 | -2,602 | -1,504 |
| Capital Expenditure | -273 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -1,531 | -1,984 | -853 | -2,602 | -1,504 |